Instrument Inactif

Autres langues Onconova Therapeutics Inc Nasdaq

Actions

US68232V1089

Recherche biotechnologique et médicale

Autres langues

14/08	Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
14/08	Traws Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
22/06	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
22/06	Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program
22/06	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
15/06	Top Premarket Decliners
15/06	Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell
12/06	Traws Pharma Provides Regulatory Update on Influenza Program
12/06	Traws Pharma Provides Regulatory Update on Influenza Program
27/05	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
27/05	Traws Pharma Advances Novel Broad-Spectrum Combination Antiviral Agent Targeting Hantavirus And Ebola Virus Disease Outbreaks
22/05	Traws Pharma Inc files for offering of up to $3.1 million in common stock
20/05	Hantavirus vaccines and treatments under development
15/05	Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
11/05	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
08/05	Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell
08/05	Traws Pharma to advance potential clinical candidates for the treatment of Hantavirus infections
08/05	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
08/05	Traws Pharma, Inc. Advances Potential Clinical Candidates For The Treatment Of Hantavirus Infections
15/04	Traws Pharma : Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)
15/04	Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
15/04	Traws Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	Traws Pharma, Inc. announced that it has received $10.009423 million in funding
15/04	Traws Pharma Announces Up to $60 Million Private Placement Financing